Eli Lilly and Co. reports it has begun clinical trials for testing therapies for COVID-19.
The drug company said it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib.
The study will investigate baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.
Baricitinib, an oral inhibitor marketed as Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis, according to Eli Lilly.
Lilly also announced that it will advance testing of an investigational antibody for use with pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS). Lilly will test whether the antibody can reduce the progression to ARDS or the need for mechanical ventilation in COVID-19 patients. This trial will begin later this month at several U.S. centers.
Source: Eli Lilly
Was this article valuable?
Here are more articles you may enjoy.
Viewpoint: How Federal Ban on Intoxicating Hemp Products Will Reshape Risk, Coverage 
AI Data Centers Are on Track to Fuel ‘Explosive’ Growth in Captive Insurance 
NC Roofers Caught in Farm Bureau’s Sting Sentenced to Probation, Restitution 
UnitedHealth Sells Interest in Florida WellMed Clinics to TPG 
